Abstract:Key PointsThe role of reactive oxygen species (ROS) in tumorigenesis is controversial, as they have been shown to have both tumour-promoting and tumour-inhibiting properties.Although low to moderate ROS levels can be beneficial to cells by promoting proliferation pathways and DNA mutagenesis, high ROS levels can instead become detrimental and induce cell death.Recent work has shown that multiple antioxidant pathways that inhibit ROS are upregulated during tumour initiation and progression.These antioxidant pathways are composed of a multitude of both metabolic and non-metabolic enzymes, many of which can be targeted for inhibition.Numerous standard chemotherapies are cytotoxic towards cancer cells owing to their ability to induce drastic increases in ROS levels.The development of novel targeted therapies against antioxidant pathways may yield considerable benefits to the field of cancer treatment.

Modulation of oxidative stress as an anticancer strategy